Keywords
How to Cite
Abstract
Introduction. Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin's lymphoma, and it accounts for up to 40% of lymphomas in patients with HIV. The widespread application of antiretroviral therapy (ART) has contributed to improving outcomes of antitumor chemotherapy (CT) for HIV-associated lymphomas, including BL. Several publications in Russia are dedicated to therapy for BL, however, there are no publications on BL in HIV-infected patients.
Aim: to study the clinical and epidemiological characteristics and to give an assessment to outcomes of BL treatment in HIV-infected patients in the Russian Federation.Matherials and methods. The study included 37 HIV-positive patients treated for Burkitt lymphoma in 10 centers of the Russian Federation from 2010 to 2021.
Results. BL in HIV-infected patients was diagnosed at a young age (median 37 years, range 21–58 years), more often in men (75,7%), in the advanced stage (Ann Arbor stage IV ― 64,7%) and with extranodal lesions (73,5%), including the central nervous system (CNS) involvement (16,1%). Main therapy protocols: EPOCH-like courses (54,1%), block schemes (32,4%). In 76% of patients, antitumor CT included rituximab, and in 91.4% it went together with ART.
The median number of therapy courses was 4 (1–8). Overall survival (OS) at 1 year was 64% (95% CI 38–82%), progression-free survival (PFS) was 59% (95% CI 34–77%). CNS involvement (p=0.0064) and conducting antitumor chemotherapy without ART was a factor worsening OS (p=0.00016) and PFS (p=0.00012).
Conclusion. Prospective multicenter studies on BL treatment in HIV-infected patients are needed for improving therapy outcomes and prognosis.
References
Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults // Blood. 2014;124(19):2913–20. doi:10.1182/blood-2014-06-538504
Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkitt lymphoma // Lancet Haematol. 2020;7(8):e594–e600. doi:10.1016/S2352-3026(20)30126-5
Dunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma // Hematol Oncol Clin North Am. 2016;30(6):1333–1343. doi:10.1016/j.hoc.2016.07.009
Meister A, Hentrich M, Wyen C, Hübel K. Malignant lymphoma in the HIV-positive patient // Eur J Haematol. 2018;101(1):119–126. doi:10.1111/ejh.13082
Alaggio R, Amador C, Anagnostopoulos I et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms // Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
Bellan C, Lazzi S, Hummel M, Palummo N et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas // Blood 2005;106:1031–6.
Abate F, Ambrosio MR, Mundo L et al. Distinct viral and mutational spectrum of Endemic Burkitt Lymphoma // PLoS Pathog. 2015;11:e1005158.
Kaymaz Y, Oduor CI, Yu H et al. Comprehensive transcriptome and mutational profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences // Mol Cancer Res. 2017;15:563–76.
Grande BM, Gerhard DS, Jiang A et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma // Blood 2019;133:1313–24.
Richter J, John K, Staiger AM et al. Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features // Br J Haematol. 2022;196:681–9.
Leoncini L. Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes // Br J Haematol. 2022;196:468–70.
Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma? // Semin Cancer Biol. 2009;19:366–76.
Fitzsimmons L, Boyce AJ, Wei W et al. Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells // Cell Death Differ. 2018;25:241–54.
Noy A. Controversies in the treatment of Burkitt lymphoma in AIDS // Curr Opin Oncol. 2010;22(5):443–8. doi:10.1097/CCO.0b013e32833d7dbe
Hernández-Ramírez RU, Qin L, Lin H et al. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicenter cohort study // Lancet HIV. 2019;6(4):e240–e249. doi:10.1016/S2352-3018(18)30360-6
Biggar RJ, Chaturvedi AK, Goedert JJ et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS // J Natl Cancer Instr. 2007;99(12):962–72. doi:10.1093/jnci/djm010
Han X, Jemal A, Hulland E et al. HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy // Cancer Epidemiol Biomarkers Prev. 2017;26(3):303–311. doi:10.1158/1055-9965.EPI-16-0595
Linke-Serinsöz E, Fend F, Quintanilla-Martinez L. Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology viewpoint // Semin Diagn Pathol. 2017;34(4):352–363. doi:10.1053/j.semdp.2017.04.003
Spina M, Tirelli U, Zagonel V et al. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients // Cancer. 1998;82(4):766–74.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline B-Cell Lymphomas Version 5.2022 ― July 12, 2022 © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [October 7, 2022]. To view the most recent and complete version of the guideline, go online to NCCN.org.
Noy A, Lee JY, Cesarman E et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma // Blood. 2015;126(2):160–6. doi:10.1182/blood-2015-01-623900
Cortes J, Thomas D, Rios A et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia // Cancer. 2002;94(5):1492–9. doi:10.1002/cncr.10365
Roschewski M, Dunleavy K, Abramson JS et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma // J Clin Oncol. 2020;38(22):2519–2529. doi:10.1200/JCO.20.00303
Dunleavy K, Pittaluga S, Shovlin M et al. Low-intensity therapy in adults with Burkitt's lymphoma // N Engl J Med. 2013;369(20):1915–25. doi:10.1056/NEJMoa1308392
Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy // AIDS. 2001;15(12):1483–91. doi:10.1097/00002030-200108170-00005
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Cancer in People with HIV Version 1.2022 ― February 3, 2022 © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [October 7, 2022]. To view the most recent and complete version of the guideline, go online to NCCN.org.
Ribrag V, Koscielny S, Bosq J et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial // Lancet. 2016;387(10036):2402–11. doi:10.1016/S0140-6736(15)01317-3
Барях Е.А., Тюрина Н.Г., Воробьев В.И. и др. Двенадцатилетний опыт терапии лимфомы Беркитта по протоколу ЛБ-М-04 // Терапевтический архив. 2015;87(7):4–14. https://doi.org/10.17116/terarkh20158774–14 [Baryakh EA, Tyurina NG, Vorobyov VI et al. Therapy for Burkitt’s lymphoma according to the BL-M-04 protocol: 12-year experience // Terapevticheskii Arkhiv. 2015;87(7):4–14. (In Russ.)]. https://doi.org/10.17116/terarkh20158774-14
Пивник А.В., Пархоменко Ю.Г., Криволапов Ю.А. и др. Соматические проблемы ВИЧ-медицины: СПИД-ассоциированные лимфомы // Онкогематология. 2007;3:27–37 [Pivnik AV, Parhomenko Y, Krivolapov YA et al. Somatic problems of HIV-medicine: AIDS-related lymphomas // Oncohematology. 2007;3:27–37 (In Russ.)].
Alvarnas JC, Le Rademacher J, Wang Y et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial // Blood. 2016;128(8):1050–1058.
Popova MO, Rogacheva YA, Nekrasova AV et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of a single center (CIC725) matched case-control study // Cellular Therapy and Transplantation (CTT). 2017;6(4). doi:10.18620/ctt-1866-8836-2017-6-4-42-51
Barta SK, Xue X, Wang D et al. A new prognostic score for AIDS-related lymphomas in the rituximab-era // Haematologica. 2014;99(11):1731–7. doi:10.3324/haematol.2014.111112
Van Heertum RL, Scarimbolo R, Wolodzko JG et al. Lugano 2014 Criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials // Drug Des Devel Ther. 2017;11:1719–1728. doi:10.2147/DDDT.S136988
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics // Bone Marrow Transplant. 2013;48:452–458. https://doi.org/10.1038/bmt.2012.244
Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms // Blood. 2016;127(20):2375–90. doi:10.1182/blood-2016-01-643569
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2022